Yang Ningbo, Li Jie, Hu Hongxia, Wang Xujiang, Shi Shaoli
Department of Psychiatry, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang City, Henan Province.
Department of Emergency Medicine, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang City, Henan Province.
Pak J Pharm Sci. 2024 Nov-Dec;37(6):1365-1373.
To explore the effect of lithium carbonate combined with olanzapine on glucose and lipid metabolism, as well as gender differences in treating bipolar disorder (BD). 110 BD patients admitted to the Fifth People's Hospital of Luoyang from February 2022 to January 2024 were retrospectively included in the study. Patients were categorized into two groups based on treatment: The single group (lithium carbonate, n = 50) and the coalition group (lithium carbonate + olanzapine, n=60). Post-treatment, the coalition group's YMRS score was 4.67±1.34 points and BRMS score was 24.93±2.30 points, both lower than the single group's YMRS score of 7.64±1.51 points and BRMS score of 34.38±2.30 points (P<0.05). The coalition group's effective rate was 96.67%, significantly higher than the single group's 82.00% (P<0.05). Post-treatment, the coalition group had lower levels of FBG, TC, TG and LDL-C than the single group, while HDL-C was higher (P<0.05). Additionally, glycolipids levels in both male and female subgroups increased post-treatment compared to pre-treatment. The efficacy of lithium carbonate sustained-release tablets combined with olanzapine in the treatment of bipolar disorder (BD) is well-established. This combination therapy can effectively alleviate manic and psychiatric symptoms, enhance patients' social functioning and improve their quality of life. Furthermore, it has a minimal impact on glucose and lipid metabolism, with no observed gender differences.
探讨碳酸锂联合奥氮平对糖脂代谢的影响以及在治疗双相情感障碍（BD）中的性别差异。回顾性纳入2022年2月至2024年1月在洛阳市第五人民医院收治的110例BD患者。根据治疗方法将患者分为两组：单药组（碳酸锂，n = 50）和联合组（碳酸锂 + 奥氮平，n = 60）。治疗后，联合组的杨氏躁狂量表（YMRS）评分为4.67±1.34分，倍克-拉范森躁狂量表（BRMS）评分为24.93±2.30分，均低于单药组的YMRS评分7.64±1.51分和BRMS评分34.38±2.30分（P<0.05）。联合组的有效率为96.67%，显著高于单药组的82.00%（P<0.05）。治疗后，联合组的空腹血糖（FBG）、总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）水平低于单药组，而高密度脂蛋白胆固醇（HDL-C）水平更高（P<0.05）。此外，与治疗前相比，男性和女性亚组治疗后的糖脂水平均有所升高。碳酸锂缓释片联合奥氮平治疗双相情感障碍（BD）的疗效已得到充分证实。这种联合治疗可以有效缓解躁狂和精神症状，增强患者的社会功能，提高生活质量。此外，它对糖脂代谢的影响最小，未观察到性别差异。
